Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for neuropathic pain in carpal tunnel syndrome
2021-006048-29Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Mater Domini
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in carpal tunnel syndrome (CTS) and Peripheral neuropathic pain comparing Botulinum toxin type A with Placebo (2 arms). Primary endpoints: Change in mean weekly average daily pain intensity, Change in weekly maximum daily pain intensity and 1 more. Started Dec 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
carpal tunnel syndrome (CTS)Peripheral neuropathic pain
Beyond the preview
Go deeper on 2021-006048-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006048-29.